China Resources Sanjiu Medical & Pharmaceutical announced that the company plans to sign an equity transfer agreement with KPC Pharmaceuticals, Inc., intending to transfer 51% equity of Huaren Shenghuo to KPC Pharmaceuticals, Inc. The transaction price is RMB 1.791 billion and the source of funds for KPC Pharmaceuticals, Inc. is its own or self-raised funds.
华润三九：拟转让昆明华润圣火药业有限公司51%股权
China Resources Sanjiu Medical & Pharmaceutical plans to transfer 51% equity of Kunming China Resources Holy Fire Pharmaceutical Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.